EXAGEN INC. Deferred Revenue Recognized
EXAGEN INC. (XGN) reported Deferred Revenue Recognized of $400.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-04
- EXAGEN INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $100.00K, a 0.00% change year-over-year.
- EXAGEN INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $100.00K.
- EXAGEN INC. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $600.00K, a 76.00% decline year-over-year.
- EXAGEN INC. contract with customer, liability, revenue recognized for the quarter ending 2024-06-30 was $3.10M, a 106.67% increase year-over-year.
- EXAGEN INC. contract with customer, liability, revenue recognized for fiscal 2025 was $400.00K.
- EXAGEN INC. contract with customer, liability, revenue recognized for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EXAGEN INC. contract with customer, liability, revenue recognized for fiscal 2023 was $3.40M.
- EXAGEN INC. contract with customer, liability, revenue recognized for fiscal 2022 was -$2.40M, a 442.86% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 6 month as first filed | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-04 | |||||||
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | $400.00K 10-K · filed 2026-03-10 | |||||||
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-04 | |||||||
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-04 | |||||||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-11 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-10 | $6.60M 10-K · filed 2025-03-11 | ||||||
| 2024-09-30 | $600.00K 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2025-11-04 | $6.20M 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | $3.10M 10-Q · filed 2024-08-05 | $0.00 10-Q · filed 2025-07-29 | $5.10M 10-Q · filed 2024-08-05 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | $2.50M 10-Q · filed 2024-05-13 | ||||||
| 2023-12-31 | $3.40M 10-K · filed 2025-03-11 | |||||||
| 2023-09-30 | $2.50M 10-Q · filed 2024-11-12 | $2.60M 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-05 | $1.80M 10-Q · filed 2024-08-05 | ||||||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-13 | |||||||
| 2022-12-31 | -$2.40M 10-K · filed 2024-03-18 | |||||||
| 2022-09-30 | $3.70M 10-Q · filed 2023-11-13 | $1.90M 10-Q · filed 2022-11-21 | -$2.50M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$1.20M 10-Q · filed 2023-08-07 | -$1.60M 10-Q · filed 2023-08-07 | ||||||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $700.00K 10-K · filed 2023-03-20 | |||||||
| 2020-12-31 | $800.00K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |